On a DART-disclosed basis, sales fell 10.7% from KRW 31.4 billion in 2022 to KRW 28.1 billion in 2023, then rose 77.8% to KRW 49.9 billion in 2024 and 56.7% to KRW 78.2 billion in 2025, increasing for two straight years from 2024 through 2025. The largest year in 2022–2025 was 2025, and the smallest was 2023.
Operating results moved from an operating loss of KRW 3.17 billion in 2022 and KRW 4.02 billion in 2023, a continued loss with widening deficit, to an operating profit of KRW 6.02 billion in 2024, a turn to profit, and KRW 15 billion in 2025, up 148.6%.
Net profit attributable to controlling shareholders went from a net loss of KRW 4.41 billion in 2023 to KRW 7.56 billion in 2024 and KRW 18.9 billion in 2025. Net income including non-controlling interests matched the controlling-shareholder figure in every year from 2022 to 2025.
Operating margin moved from -10.1% in 2022 and -14.3% in 2023 to 12.1% in 2024 and 19.1% in 2025. Securities reports tied the 2024 turn to profit to rising hydrogel mask orders and higher utilization.
The debt ratio fell from 102.9% in 2023 to 37.7% in 2025, with year-end 2025 total equity of KRW 41 billion and total liabilities of KRW 15.5 billion. Operating cash flow rose from KRW 2.7 million... more precisely KRW 272 million in 2024 to KRW 20.7 billion in 2025.
On a quarterly basis, sales went from KRW 23.6 billion in Q3 2025 and KRW 12.2 billion in Q4 2025, down 48.4% from the prior quarter, to KRW 29.4 billion in Q1 2026, KRW 49.2 billion in Q2 2026, and KRW 52.8 billion in Q3 2026, rising for three straight quarters.
Operating profit fell to KRW 104 million in Q4 2025, then rose to KRW 3.41 billion in Q1 2026 and KRW 9.99 billion in Q2 2026, before declining 23.6% to KRW 7.63 billion in Q3 2026. Q3 2026 sales rose 124.2% year on year, but operating profit rose only 35.1%, so profit grew more slowly than sales.
Net profit attributable to controlling shareholders over the four quarters from Q4 2025 to Q3 2026 totaled KRW 28.3 billion.